Overview of the Partnership
Iris Biotech GmbH, based in the Bavarian town of Marktredwitz near the German-Czech border, is one of Europe's leading specialist suppliers of Fmoc-protected amino acid building blocks, SPPS reagents, and peptidomimetic compounds. The company was founded in 1998 by chemists from the University of Bayreuth and has built a formidable reputation for catalogue breadth, technical expertise, and exceptional customer service across the European and North American research chemistry markets.
GL Biochem's partnership with Iris Biotech was formalised in 2017 following a period of informal cross-referencing of each other's catalogues at international peptide conferences. The two companies recognised early that their businesses were genuinely complementary: Iris Biotech excels in small-quantity, highly specialised exotic building blocks manufactured at their German facility, while GL Biochem's Shanghai operations provide unmatched economies of scale for high-volume standard and semi-exotic building blocks. By collaborating rather than competing, both companies can offer their customers a broader and better-priced catalogue than either could provide independently.
Co-Manufacturing & European Stock
The commercial heart of the GL Biochem–Iris Biotech partnership is a co-manufacturing and European stock-holding arrangement. GL Biochem manufactures approximately 200 high-volume Fmoc and Boc amino acid building blocks on behalf of Iris Biotech at GL Biochem's Shanghai facility. These products are manufactured to Iris Biotech's catalogue specifications, tested by GL Biochem's QC laboratory, and supplied to Iris Biotech in bulk for repacking and EU catalogue listing.
From Iris Biotech's perspective, outsourcing the synthesis of high-volume standard building blocks to GL Biochem allows their German synthesis team to focus on higher-value, lower-volume exotic building blocks and peptidomimetics — where Iris Biotech's synthetic chemistry expertise is genuinely differentiated and where the economics of large-scale synthesis do not apply. For GL Biochem, the arrangement provides Iris Biotech as a large, reliable European customer with predictable order volumes that anchor GL Biochem's high-volume synthesis scheduling.
Iris Biotech maintains European stock of GL Biochem-manufactured building blocks at four locations:
- Marktredwitz, Germany: Primary warehouse and repacking facility — all GL Biochem bulk material is received here, QC-checked by Iris Biotech's incoming QC team, and repacked into catalogue pack sizes
- Basel, Switzerland: Regional hub serving Swiss pharmaceutical cluster customers — stocking fast-moving items with 24-hour delivery to Basel area
- Amsterdam, Netherlands: Benelux distribution point — serving Netherlands, Belgium, and Luxembourg
- United Kingdom: Post-Brexit UK distribution point maintaining UK stock to avoid customs delays for British academic and pharmaceutical customers
The result is that a researcher in Germany, Switzerland, the Netherlands, or the UK ordering a GL Biochem-manufactured Fmoc amino acid from the Iris Biotech catalogue typically receives their order the next working day — a dramatic improvement over the 7–14 day lead time that would apply to direct ordering from Shanghai.
Technical Collaboration & Peptidomimetics
Beyond the commercial supply arrangement, GL Biochem and Iris Biotech maintain an active technical collaboration focused on the development of new peptidomimetic building blocks. Iris Biotech's synthetic chemistry team — led by PhD chemists with deep expertise in peptidomimetics and heterocyclic chemistry — frequently encounters challenging synthesis targets for which GL Biochem's scale-up capabilities are essential once a viable route has been established at small scale in Marktredwitz.
The joint development pipeline currently includes three classes of novel building blocks:
- Aza-amino acid building blocks: Where a backbone CH is replaced by N — important for protease-resistant peptidomimetics. Iris Biotech has developed the synthetic routes at 10–50 mmol scale; GL Biochem is scaling to 500+ mmol for commercial catalogue quantities
- Sulfonamide isosteres: Replacement of amide bonds with sulfonamide groups to improve pharmacokinetic profiles — targeting pharmaceutical customers working on oral bioavailability enhancement
- Conformationally constrained building blocks: Bicyclic and spiro amino acid derivatives that lock peptide backbone dihedral angles — relevant to the growing interest in macrocyclic peptide drug discovery
GL Biochem and Iris Biotech have agreed a joint IP framework for these development projects: Iris Biotech retains European sales rights for quantities up to 1 kg per year; GL Biochem retains Asian and North American sales rights and handles all production above 1 kg/year regardless of geography. This arrangement provides both companies with a clear commercial incentive to invest in joint development while avoiding territorial conflicts.
Growing the European Research Market Together
The GL Biochem–Iris Biotech partnership has proven to be one of the most effective market development collaborations in European research chemicals. By combining GL Biochem's manufacturing scale and cost efficiency with Iris Biotech's European brand recognition, customer relationships, and logistics infrastructure, the two companies have collectively grown the addressable market for high-quality Fmoc amino acid building blocks in Europe — bringing researchers who previously relied on lower-quality or inconsistently supplied alternatives into the premium building block market.
GL Biochem and Iris Biotech co-exhibit at the European Peptide Symposium (EPS) every two years, presenting a joint booth that allows both companies to present their collaborative capabilities to the European peptide research community. Joint technical presentations at EPS 2018, 2020, and 2022 — covering the joint development of exotic building blocks and the European stock-holding arrangement — attracted significant interest from pharmaceutical company procurement teams and generated substantial new business for both companies.
Looking ahead, the two companies are exploring the feasibility of a joint European marketing entity — a potential Iris Biotech–GL Biochem collaboration brand — that would present an integrated catalogue of European-manufactured speciality items and Chinese-manufactured high-volume items under a single ordering platform, further simplifying procurement for European customers while preserving both companies' individual brand identities.